- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Outlook Arena
- Oct 30, 2009 - Aventis: India, exports perform
Aventis: India, exports perform
Oct 30, 2009
Performance summary
- Net sales grow by a mere 6% YoY during 3QCY09 largely due to the absence of sales from the vaccine ‘Rabipur’, which were present in 3QCY08. However, on excluding the same, sales grow by a healthy 14% YoY.
- Operating margins fall by 2.4% to 21.1% during the quarter due to higher staff costs and other expenditure (as percentage of sales).
- Decline in operating profits and other income takes its toll on the bottomline, which falls by 2% YoY.
| (Rs m) | 3QCY08 | 3QCY09 | Change | 9mCY08 | 9mCY09 | Change |
| Net sales | 2,616 | 2,775 | 6.1% | 7,501 | 7,958 | 6.1% |
| Expenditure | 2,000 | 2,189 | 9.5% | 5,745 | 6,058 | 5.4% |
| Operating profit (EBIDTA) | 616 | 586 | -4.9% | 1,756 | 1,900 | 8.2% |
| EBDITA margin (%) | 23.5% | 21.1% | 23.4% | 23.9% | ||
| Other income | 116 | 99 | -14.7% | 271 | 273 | 0.7% |
| Interest | - | - | 1 | - | ||
| Depreciation | 43 | 44 | 2.3% | 138 | 129 | -6.5% |
| Profit before tax | 689 | 641 | -7.0% | 1,888 | 2,044 | 8.3% |
| Tax | 243 | 203 | -16.5% | 679 | 730 | 7.5% |
| Profit after tax/(loss) | 446 | 438 | -1.8% | 1,209 | 1,314 | 8.7% |
| Net profit margin (%) | 17.0% | 15.8% | 16.1% | 16.5% | ||
| No. of shares (m) | 23.0 | 23.0 | ||||
| Diluted earnings per share (Rs)* | 76.8 | |||||
| Price to earnings ratio (x)* | 20.5 |
What has driven performance in 3QCY09?
- Aventis clocked a 6% YoY growth in sales during 3QCY09. Having said that, this was largely due to the absence of sales from the vaccine ‘Rabipur’ this quarter, which were present in 3QCY08. Thus, on excluding the same, sales registered a healthy 14% YoY growth largely led by the domestic (up 16% YoY) business. As far as ‘Rabipur’ is concerned, Aventis had formed a JV with Novartis Vaccines called Chiron, in which the former had 49% stake for the distribution of ‘Rabipur’ in India. Since Novartis Vaccines chose not to renew the contract, there were no sales from ‘Rabipur’ this quarter and will not be reflected in the coming quarters as well. As far as exports are concerned, while the 7% YoY growth during the quarter was lukewarm, for the nine month period exports grew at a robust pace of 24% YoY.
Revenue break-up (Rs m) 3QCY08 3QCY09 Change 9mCY08 9mCY09 Change Domestic sales - Others 1,743 2,025 16.2% 4,836 5,534 14.4% Domestic sales - 'Rabipur' 214 - 884 92 -89.6% Total domestic sales 1,957 2,025 3.5% 5,720 5,626 -1.6% Export sales 522 560 7.3% 1,414 1,747 23.6% Total 2,479 2,585 4.3% 7,134 7,373 3.4% - Operating margins fell by 2.4% to 21.1% during the quarter. This was largely due to a rise in staff costs from 11.1% in 3QCY08 to 13.7% in 3QCY09 and other expenditure (as percentage of sales). Raw material costs, despite falling from 46.6% of sales in 3QCY08 to 45.6% in 3QCY09, were not enough in arresting the decline in operating margins. For the nine month period, however, operating margins improved marginally by 0.5% to 23.9%.
- Due to the 5% YoY decline in operating profits and 15% YoY reduction in other income, Aventis’ bottomline fell by 2% YoY during the quarter. This is despite a 17% YoY drop in tax expenses. For the nine month period, the company reported a 9% YoY growth in net profits in tandem with the 8% YoY growth in operating profits.
What to expect?
At the current price of Rs 1,573, the stock is trading at a multiple of 17.3 times our estimated CY11 earnings. In the domestic market, Aventis’ strong presence in the fast-growing lifestyle segment along with its focus on strategic brands are expected to be the key growth drivers going forward. Having said that, we expect the pressure on margins to continue. Though inconsistent in the past, the fact that the exports segment witnessed a strong growth in sales during the last few quarters is an encouraging sign. Having said that, while we remain positive on the growth prospects of the company, valuations appear to be on the higher side.|
| |
SANOFI INDIA SHARE PRICE
Sep 21, 2018 (Close)
TRACK SANOFI INDIA
- Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SANOFI INDIA
SANOFI INDIA - TEVA PHARMA COMPARISON
COMPARE SANOFI INDIA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.